Annals of Military and Health Sciences Research

Published by: Kowsar
Crossmark

Efficacy of Oral Alendronate Versus Zoledronic Acid on Postmenopausal Osteoporosis

Sharif Najafi 1 , Zahra Rezasoltani 1 , Kamran Azma 1 , Saman Nayeb Abbas 1 , Mehrdad Aghaei 2 and Ehsan Sanati 1 , *
Authors Information
1 Department of Physical Medicine and Rehabilitation, AJA University of Medical Sciences, Tehran, Iran
2 Department of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Article information
  • Annals of Military and Health Sciences Research: 17 (2); e86960
  • Published Online: May 29, 2019
  • Article Type: Research Article
  • Received: December 1, 2018
  • Revised: April 10, 2019
  • Accepted: May 7, 2019
  • DOI: 10.5812/amh.86960

To Cite: Najafi S, Rezasoltani Z, Azma K, Nayeb Abbas S, Aghaei M, et al. Efficacy of Oral Alendronate Versus Zoledronic Acid on Postmenopausal Osteoporosis, Ann Mil Health Sci Res. Online ahead of Print ; 17(2):e86960. doi: 10.5812/amh.86960.

Abstract
Copyright © 2019, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Nalamachu SR, Nalamasu S. Osteoporosis (primary). 2011, [cited Feb 14]. Available from: http://emedicine.medscape.com/.
  • 2. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. 2008, [cited May 5]. Available from: http://www.iofbonehealth.org/facts-and-statistics.html.
  • 3. Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of osteoporosis. Clin Ther. 2015;37(8):1837-50. doi: 10.1016/j.clinthera.2015.06.006. [PubMed: 26163201].
  • 4. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453-60. doi: 10.1185/030079905X61875. [PubMed: 16197664].
  • 5. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17(6):922-8. doi: 10.1007/s00198-006-0085-2. [PubMed: 16609824].
  • 6. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22. doi: 10.4065/81.8.1013. [PubMed: 16901023].
  • 7. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(6):922-8. doi: 10.1016/j.bone.2005.10.022. [PubMed: 16330270].
  • 8. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-61. doi: 10.1056/NEJMoa011807. [PubMed: 11870242].
  • 9. [No authors listed]. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. [PubMed: 7941614].
  • 10. Lyles KW, Schenck AP, Colon-Emeric CS. Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents. Osteoporos Int. 2008;19(8):1225-33. doi: 10.1007/s00198-008-0569-3. [PubMed: 18301857]. [PubMed Central: PMC2562901].
  • 11. Osteoporosis and bone physiology. Merlot Classics; 2003. Available from: http://courses.washington.edu/bonephys/opbmdtz.html.
  • 12. Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic. Intern Med J. 2011;41(2):186-90. doi: 10.1111/j.1445-5994.2010.02198.x. [PubMed: 20214696].
  • 13. Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, et al. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012;97(12):4481-90. doi: 10.1210/jc.2012-2804. [PubMed: 23024190]. [PubMed Central: PMC3591679].
  • 14. Ferguson L, Panarelli M, Dargie R. Zoledronic acid vs alendronate in the management of osteoporosis. Bone Abstr. 2013. doi: 10.1530/boneabs.1.PP443.
  • 15. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25(10):2239-50. doi: 10.1002/jbmr.119. [PubMed: 20499357].
  • 16. Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, et al. Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: A 2-year clinical study. Endocr Pract. 2018;24(2):179-88. doi: 10.4158/EP171910.OR. [PubMed: 29466057].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments